CD20

Summary

Gene Symbol: CD20
Description: membrane spanning 4-domains A1
Alias: Bp35, CD20, CVID5, LEU-16, MS4A2, B-lymphocyte antigen CD20, B-lymphocyte cell-surface antigen B1, CD20 antigen, CD20 receptor, leukocyte surface antigen Leu-16, membrane-spanning 4-domains, subfamily A, member 1
Species: human

Top Publications

  1. ncbi Validation of a capillary isoelectric focusing method for the recombinant monoclonal antibody C2B8
    G Hunt
    Department of Quality Control Clinical Development, Genentech Inc, South San Francisco, CA 94080, USA
    J Chromatogr A 800:355-67. 1998
  2. ncbi Effect of interferon-alpha on CD20 antigen expression of B-cell chronic lymphocytic leukemia
    S Sivaraman
    Rush Cancer Institute, Rush Presbyterian St Luke s Medical Center, Chicago, IL 60612 3750, USA
    Cytokines Cell Mol Ther 6:81-7. 2000
  3. ncbi Mechanism of action of rituximab
    D G Maloney
    Fred Hutchison Cancer Research Center, Seattle, WA 98109, USA
    Anticancer Drugs 12:S1-4. 2001
  4. ncbi Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma
    Jonathan W Friedberg
    Lymphoma Program, James P Wilmot Cancer Center, University of Rochester, Rochester, NY 14642, USA
    Expert Rev Anticancer Ther 4:18-26. 2004
  5. doi Combined therapy with rituximab plus cyclophosphamide/vincristine/prednisone for Sjogren's syndrome-associated B-cell non-Hodgkin's lymphoma
    J Carbone
    Department of Immunology, University Hospital Gregorio Maranon, Dr Esquerdo 46, 28007, Madrid, Spain
    Clin Rev Allergy Immunol 34:80-4. 2008
  6. ncbi Store-operated cation entry mediated by CD20 in membrane rafts
    Haidong Li
    Immunology Research Group, Department of Biochemistry and Molecular Biology, University of Calgary Health Sciences Center, 3330 Hospital Drive NW, Calgary, Alberta T2N 4N1, Canada
    J Biol Chem 278:42427-34. 2003
  7. doi Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling
    Claire A Walshe
    Cancer Sciences Division, General Hospital, Southampton University School of Medicine, Southampton SO16 6YD, United Kingdom
    J Biol Chem 283:16971-84. 2008
  8. ncbi CD3-negative, CD20-positive T-cell prolymphocytic leukemia: case report and review of the literature
    Kenji Tamayose
    Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan
    Am J Hematol 71:331-5. 2002
  9. doi Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients
    Constantine S Tam
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 141:36-40. 2008
  10. ncbi Rapid method for monitoring galactosylation levels during recombinant antibody production by electrospray mass spectrometry with selective-ion monitoring
    H Z Wan
    Department of Manufacturing Sciences, Genentech, Inc, South San Francisco, CA 94080, USA
    J Chromatogr A 913:437-46. 2001

Research Grants

  1. Mechanism of Antibody Therapy in Human B Cell Lymphoma
    Wen Kai Weng; Fiscal Year: 2007
  2. BRENDA MARIE SANDMAIER; Fiscal Year: 2016
  3. Sherie L Morrison; Fiscal Year: 2015
  4. Targeted therapy of pancreatic cancer with in vivo radionuclide generator
    Ekaterina Dadachova; Fiscal Year: 2012
  5. Rituximab Therapy in Refractory Adult and Juvenile IIM
    CHARLES ODDIS; Fiscal Year: 2010
  6. Rituximab Therapy in Refractory Adult and Juvenile IIM
    CHARLES ODDIS; Fiscal Year: 2009
  7. John M Timmerman; Fiscal Year: 2014
  8. Oliver W Press; Fiscal Year: 2015
  9. Edward A Neuwelt; Fiscal Year: 2016
  10. Oliver W Press; Fiscal Year: 2016

Detail Information

Publications422 found, 100 shown here

  1. ncbi Validation of a capillary isoelectric focusing method for the recombinant monoclonal antibody C2B8
    G Hunt
    Department of Quality Control Clinical Development, Genentech Inc, South San Francisco, CA 94080, USA
    J Chromatogr A 800:355-67. 1998
    ..for the purpose of determining the identity and charge distribution of mouse/human chimeric antibody to human CD20 antigen (C2B8)...
  2. ncbi Effect of interferon-alpha on CD20 antigen expression of B-cell chronic lymphocytic leukemia
    S Sivaraman
    Rush Cancer Institute, Rush Presbyterian St Luke s Medical Center, Chicago, IL 60612 3750, USA
    Cytokines Cell Mol Ther 6:81-7. 2000
    ..There was no statistically significant increase in CD20 antigen expression on normal lymphocytes following cytokine exposure...
  3. ncbi Mechanism of action of rituximab
    D G Maloney
    Fred Hutchison Cancer Research Center, Seattle, WA 98109, USA
    Anticancer Drugs 12:S1-4. 2001
    The CD20 antigen is strongly and stably expressed on cells of the B-cell lineage, but not on stem cells, and is thus an ideal target antigen for antibody therapy of B-cell malignancies...
  4. ncbi Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma
    Jonathan W Friedberg
    Lymphoma Program, James P Wilmot Cancer Center, University of Rochester, Rochester, NY 14642, USA
    Expert Rev Anticancer Ther 4:18-26. 2004
    Tositumomab is an immunoglobulin G murine monoclonal antibody that binds to the CD20 antigen on the surface of normal and malignant human B-cells...
  5. doi Combined therapy with rituximab plus cyclophosphamide/vincristine/prednisone for Sjogren's syndrome-associated B-cell non-Hodgkin's lymphoma
    J Carbone
    Department of Immunology, University Hospital Gregorio Maranon, Dr Esquerdo 46, 28007, Madrid, Spain
    Clin Rev Allergy Immunol 34:80-4. 2008
    ..Optimal treatment for NHL-complicating SS is not clearly established. NHL, which expresses the CD20 antigen on tumor cell surfaces, is a disease entity candidate to treatment with anti-CD20 monoclonal antibodies...
  6. ncbi Store-operated cation entry mediated by CD20 in membrane rafts
    Haidong Li
    Immunology Research Group, Department of Biochemistry and Molecular Biology, University of Calgary Health Sciences Center, 3330 Hospital Drive NW, Calgary, Alberta T2N 4N1, Canada
    J Biol Chem 278:42427-34. 2003
    ..The molecular identity of these channels is not known. Ectopic expression of the raft-associated tetraspan protein CD20 in Chinese hamster ovary cells introduced a novel SOC entry pathway that was permeable to strontium as well as to ..
  7. doi Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling
    Claire A Walshe
    Cancer Sciences Division, General Hospital, Southampton University School of Medicine, Southampton SO16 6YD, United Kingdom
    J Biol Chem 283:16971-84. 2008
    The anti-CD20 monoclonal antibody (mAb) rituximab is now routinely used for the treatment of non-Hodgkins lymphoma and is being examined in a wide range of other B-cell disorders, such as rheumatoid arthritis...
  8. ncbi CD3-negative, CD20-positive T-cell prolymphocytic leukemia: case report and review of the literature
    Kenji Tamayose
    Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan
    Am J Hematol 71:331-5. 2002
    We report a case of CD3-negative, CD20-positive T-cell prolymphocytic leukemia (T-PLL). The leukemic cells were of medium-to-large size, mature-looking, and did not have cytoplasmic granules...
  9. doi Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients
    Constantine S Tam
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 141:36-40. 2008
    ..Patients were classified using the Dohner hierarchial classification. The median numbers of CD20 antigen sites by FISH subtypes were: 17p- (n = 26), 9341 per cell; 11q- (n = 42), 5886 per cell; +12 (n = 93), 23 603 ..
  10. ncbi Rapid method for monitoring galactosylation levels during recombinant antibody production by electrospray mass spectrometry with selective-ion monitoring
    H Z Wan
    Department of Manufacturing Sciences, Genentech, Inc, South San Francisco, CA 94080, USA
    J Chromatogr A 913:437-46. 2001
    ..to an HPLC system to quantify the glycoform amounts found on a recombinant antibody that binds to the human CD20 antigen. Samples from the recombinant antibody process are reduced and injected directly into the HPLC system where the ..
  11. ncbi The involvement of matrix metalloproteinases and inflammation in lumbar disc herniation
    Y Matsui
    Department of Orthopedic Surgery, Toyohashi Municipal Hospital, Aichi, Japan
    Spine (Phila Pa 1976) 23:863-8; discussion 868-9. 1998
    ..discs were stained with hematoxylin-eosin or toluidine blue or were immunostained with monoclonal antibodies to CD20, CD45RO, and CD68, anti-MMP-1, and anti-MMP-3, using the avidin-biotin-peroxidase complex method...
  12. ncbi Distinguishing B and T lymphocytes by scanning electron microscopy
    J A Terzakis
    Kalvin Electron Microscope Laboratory, Department of Pathology, Lenox Hill Hospital, New York, NY 10021, USA
    Ultrastruct Pathol 24:205-9. 2000
    ..of T lymphocytes and B lymphocytes was verified by immunocytochemical staining respectively with CD3 and CD20 antisera...
  13. ncbi Mitoxantrone as a single agent in pretreated metastatic breast cancer: effects on T lymphocyte subsets and their relation to clinical response
    S Barni
    Divisione di Radioterapia Oncologica, Ospedale San Gerardo, Monza, Milano, Italy
    Tumori 77:227-31. 1991
    ..Moreover, in 8/16 patients, B lymphocytes (CD20), T suppressor cells (CD8+/CD57+), T cytotoxic cells (CD8+/CD57-), NK (CD16) and IL-2 receptor-expressing cells (..
  14. ncbi Granulomatous slack skin in childhood
    F M Camacho
    Department of Medical-Surgical Dermatology, Hospital Universitario Virgen Macarena, Universidad de Sevilla, Spain
    Pediatr Dermatol 14:204-8. 1997
    ..The lymphoid cells showed the following immunophenotype: CD43+ (MT1), CD45+, CD45RO+, CD20-. The phenotype of the giant cells was lysozyme positive, CD68+ and Mac387-...
  15. ncbi Immunological effects following administration of interferon-alpha in patients with chronic hepatitis C virus (cHCV) infection
    E Jirillo
    Faculty of Medicine, University of Bari, Italy
    Immunopharmacol Immunotoxicol 18:355-74. 1996
    ..patients IFN-alpha administration gave rise to an increase (above normality) of CD3+, CD4+, CD8+, CD14+, CD16+ and CD20+ cell absolute numbers, while in one patient the same markers dramatically dropped below normal range...
  16. ncbi [Distribution and force spectroscopy of CD20 antigen-antibody binding on the B cell surface]
    Qiulan Wang
    Department of Chemistry, Jinan University, Guangzhou 510632, China
    Sheng Wu Gong Cheng Xue Bao 27:131-6. 2011
    The lower expression of CD20 antigen molecules on the B cell membrane is the primary characteristic of B-chronic lymphocytic leukemia (B-CLL)...
  17. ncbi Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura
    R Stasi
    Department of Medical Sciences, Regina Apostolorum Hospital, Albano Laziale, Italy
    Blood 98:952-7. 2001
    The role of rituximab, a chimeric monoclonal antibody directed against the CD20 antigen, in the treatment of patients with chronic idiopathic thrombocytopenic purpura (ITP) has not been determined...
  18. ncbi Construction and characterization of a fusion protein of single-chain anti-CD20 antibody and human beta-glucuronidase for antibody-directed enzyme prodrug therapy
    H J Haisma
    Departments of Medical Oncology and Otolaryngology Head and Neck Surgery, Academic Hospital Vrije Universiteit, Amsterdam, The Netherlands
    Blood 92:184-90. 1998
    The CD20 antigen is an attractive target for specific treatment of B-cell lymphoma...
  19. ncbi [Combination of thalidomide and rituximab in suppressing myeloma cells in vitro]
    Juan Li
    Department of Hematology, First Affiliated Hospital, Sun Yat Sen University, Guangzhou 510080, P R China
    Ai Zheng 21:1324-7. 2002
    The efficiency of rituximab (Mabthera) is related to CD20 expression density on cell membrane...
  20. ncbi Expression of adhesion molecules in the host response to colon carcinoma
    B F Banner
    Department of Pathology, University of Massachusetts Medical Center, Worcester 01655, USA
    Ultrastruct Pathol 19:113-8. 1995
    ..samples were stained by a labeled avidin-biotin technique using primary antibodies to LFA-1 (CD11a), CD2, CD4, CD8, CD20, CD68, HLA-DR, ICAM-1 (CD54), and VCAM-1...
  21. ncbi Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study
    B Coiffier
    Service d Hematologie, Centre Hospitalier Lyon Sud, Pierre Benite, France the Service d Hématologie, Hopital Henri Mondor, Creteil, France the Klinik 1 fur Innere Medezin, Universitat zu Koln, Koln, Germany
    Blood 92:1927-32. 1998
    Rituximab, a chimeric monoclonal antibody that binds specifically to the CD20 antigen, induced objective responses in 50% of patients with low-grade or follicular B-cell lymphoma...
  22. ncbi Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, 93 513 Lodz, Pabianicka 62, Poland
    Leuk Lymphoma 45:937-44. 2004
    ..Twenty six CD20 antigen positive patients, 15 with B-cell chronic lymphocytic leukemia (B-CLL) and 11 with low grade non-Hodgin's ..
  23. ncbi Existence of leukemic clones resistant to both imatinib mesylate and rituximab before drug therapies in a patient with Philadelphia chromosome-positive acute lymphocytic leukemia
    Takaaki Hato
    Division of Blood Transfusion, Ehime University School of Medicine, Shitsukawa, Shigenobu, Onsen gun, Ehime, Japan
    Int J Hematol 80:62-6. 2004
    Imatinib mesylate and rituximab are molecularly targeted drugs against the BCR-ABL fusion protein and the CD20 antigen, respectively. Although these drugs have excellent anticancer effects, a major concern is drug resistance...
  24. ncbi Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand?
    P Cacoub
    Universite Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Paris, France
    Ann Rheum Dis 67:283-7. 2008
    ..Recent reports describe the use of monoclonal antibodies directed to CD20 antigen (rituximab), a transmembrane protein expressed on pre-B lymphocytes and mature lymphocytes...
  25. ncbi Complete remission of a primary cutaneous B-cell lymphoma of the lower leg by first-line monotherapy with the CD20-antibody rituximab
    B Bonnekoh
    Department of Dermatology and Venereology, Otto von Guericke University, Leipziger Strasse 44, 39120 Magdeburg, Germany
    J Cancer Res Clin Oncol 128:161-6. 2002
    Rituximab is a genetically engineered antibody recognizing the CD20 antigen known to be expressed by more than 95% of B-cell lymphomas...
  26. ncbi Current status of cancer therapy with radiolabeled monoclonal antibody
    Noboru Oriuchi
    Department of Diagnostic Radiology and Nuclear Medicine, Gunma University Graduate School of Medicine, 3 39 22 Showa machi, Maebashi 371 8511, Japan
    Ann Nucl Med 19:355-65. 2005
    ..using 131I- and 90Y-labeled anti-CD20 monoclonal antibodies is now indicated for the treatment of patients with CD20 antigen-expressing relapsed or refractory, low-grade or transformed non-Hodgkin's lymphoma (NHL), including patients ..
  27. ncbi Predictive significance of the cut-off value of CD20 expression in patients with B-cell lymphoma
    Mateja Horvat
    Bayer d o o, 1000 Ljubljana, Slovenia
    Oncol Rep 24:1101-7. 2010
    ..patients who achieved complete response after rituximab therapy had a significantly higher expression of the CD20 antigen (p=0.018) than those whose disease only stabilized after rituximab therapy...
  28. ncbi Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1
    Raffit Hassan
    Laboratory of Molecular Biology, National Cancer Institute, NIH, Bethesda, Maryland, USA
    Clin Cancer Res 10:16-8. 2004
    Rituximab, a humanized monoclonal antibody directed to the CD20 antigen present on B lymphocytes, could potentially abrogate the humoral immune response to murine monoclonal antibodies or immunotoxins by depleting antibody-producing B ..
  29. ncbi [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma]
    Hui Qiang Huang
    State Key Laboratory of Oncology in South China, Guangzhou, Gongdong 510060, P R China
    Ai Zheng 25:486-9. 2006
    ..Rituximab, a chimeric anti-CD20 antigen, in combination with CHOP or CHOP-like chemotherapy may improve both disease-freely survival and overall ..
  30. doi Antitumor effects of an engineered and energized fusion protein consisting of an anti-CD20 scFv fragment and lidamycin
    Hong Fang
    Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
    Sci China Life Sci 54:255-62. 2011
    Antibody-based fusion proteins are the next generation of antibody therapies for cancer and other diseases. CD20 antigen, which is overexpressed on cell membranes in nearly 95% of cases of B-cell Non-Hodgkin's Lymphoma, is an attractive ..
  31. ncbi Cloning of a complementary DNA encoding a new mouse B lymphocyte differentiation antigen, homologous to the human B1 (CD20) antigen, and localization of the gene to chromosome 19
    T F Tedder
    Division of Tumor Immunology, Dana Farber Cancer Institute, Boston, MA 02115
    J Immunol 141:4388-94. 1988
    The human B1 (CD20) molecule is a differentiation Ag found only on the surface of B lymphocytes. This structurally unique phosphoprotein plays a role in the regulation of human B cell proliferation and differentiation...
  32. doi 99mTc-labelled rituximab, a new non-Hodgkin's lymphoma imaging agent: first clinical experience
    Tanja Gmeiner Stopar
    Department for Nuclear Medicine, University Medical Centre Ljubljana, Slovenia
    Nucl Med Commun 29:1059-65. 2008
    ..was performed to explore the possibility of using Tc-rituximab as an imaging agent to assess expression of CD20 antigen in patients with B-cell non-Hodgkin's lymphoma (NHL) before (radio) immunotherapy, for staging and subsequent ..
  33. doi Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin's lymphoma after rituximab therapy
    Akiko Miyagi Maeshima
    Clinical Laboratory, National Cancer Center Hospital, Tokyo, Japan
    Cancer Sci 100:54-61. 2009
    Rituximab is a chimeric monoclonal antibody that recognizes the CD20 antigen. It has been used to treat B-cell non-Hodgkin lymphoma (B-NHL), but recently rituximab resistance has been a cause for concern...
  34. doi CD20 antigen imaging with ¹²⁴I-rituximab PET/CT in patients with rheumatoid arthritis
    L Tran
    Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute Slotervaart Hospital, Amsterdam, The Netherlands
    Hum Antibodies 20:29-35. 2011
    Visualization of the CD20-antigen expression could provide a tool to localize sites of inflammation and could be of additive value in the diagnosis, and subsequently, in the treatment follow-up of patients with rheumatoid arthritis...
  35. ncbi Canine CD20 gene
    Rui Kano
    Department of Pathobiology, Nihon University School of Veterinary Medicine, 1866 Kameiho, Fujisawa, Kanagawa 252 8510, Japan
    Vet Immunol Immunopathol 108:265-8. 2005
    The human CD20 antigen, a 35kDa cell surface nonglycosylated hydrophobic phoshpoprotein is expressed consistently on almost all human B-cells, and its monoclonal antibody is used for the therapy on human B-cell lymphoma...
  36. ncbi [Density expression of the CD20 antigen on population of tumor cells in patients with chronic B-lymphocyte lymphoproliferative diseases]
    V Sukova
    Laborator flow cytometrie a celulární terapie LF MU a FN, Brno
    Cas Lek Cesk 145:712-6; discussion 716-7. 2006
    ..Therefore, the authors analyzed and compared the densities of the CD20 antigen in patients with chronic lymphoproliferative diseases.
  37. doi Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels
    Myron S Czuczman
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Clin Cancer Res 14:1561-70. 2008
    ..Significant changes in surface CD20 antigen expression were shown in RRCL...
  38. doi B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression
    Andrea Borgerding
    Department of Haematology and Oncology, Georg August University of Gottingen, Gottingen, Germany
    Exp Hematol 38:213-21. 2010
    ..Resistance to this treatment occurs, although CD20 antigen is expressed on the tumor cells.
  39. doi The pharmacokinetics of ¹²⁴I-rituximab in patients with rheumatoid arthritis
    L Tran
    Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute Slotervaart Hospital, Amsterdam, The Netherlands
    Hum Antibodies 20:7-14. 2011
    Rheumatoid arthritis is a destructive inflammatory joint disorder. Pre- and mature B-cells, characterized by CD20 antigen expression, play an important role in the inflammatory process...
  40. ncbi Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program
    P McLaughlin
    Department of Hematology, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    J Clin Oncol 16:2825-33. 1998
    The CD20 antigen is expressed on more than 90% of B-cell lymphomas. It is appealing for targeted therapy, because it does not shed or modulate...
  41. ncbi Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma
    A Harjunpää
    The Department of Bacteriology and Immunology Haartman Institute, University of Helsinki, Finland
    Leuk Lymphoma 42:731-8. 2001
    Rituximab (IDEC-C2B8, Mabthera, Rituxan), a chimeric monoclonal antibody against the B-cell specific CD20-antigen, has been demonstrated to be effective in the treatment of non-Hodgkin's B-cell lymphoma (B-NHL)...
  42. ncbi Rituximab in combination with vinorelbine/gemcitabine chemotherapy in patients with primary refractory or early relapsed T cell rich B cell lymphoma. A pilot study
    Nikolaos Xiros
    Second Department of Internal Medicine Propaedeutic, Evangelismos Hospital, University of Athens, Ipsilandou 45 47, 106 76 Athens, Greece
    Leuk Res 27:1097-9. 2003
    Rituximab is a chimeric monoclonal antibody that binds specifically to the CD20 antigen expressed in most B cell lymphomas...
  43. ncbi (99m)Tc-rituximab radiolabelled by photo-activation: a new non-Hodgkin's lymphoma imaging agent
    T Gmeiner Stopar
    Department for Nuclear Medicine, University Medical Centre Ljubljana, Zaloska 7, 1525 Ljubljana Slovenia
    Eur J Nucl Med Mol Imaging 33:53-9. 2006
    ..It is directed against the CD20 antigen, which is expressed by 95% of B-cell NHLs...
  44. ncbi Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single center
    Ashokkumar B Jain
    Thomas E Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA, USA
    Transplantation 80:1692-8. 2005
    ..Many PTLD are B cell in origin have CD20 antigen on the cell surface...
  45. doi First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial
    Anton Hagenbeek
    University Medical Center Utrecht, Department of Hematology, Utrecht, The Netherlands
    Blood 111:5486-95. 2008
    Ofatumumab is a unique monoclonal antibody that targets a distinct small loop epitope on the CD20 molecule...
  46. pmc Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells
    Rosa Lapalombella
    Division of Hematology Oncology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, USA
    Blood 112:5180-9. 2008
    ..The anti-CD20 antibody rituximab is active in CLL and represents a rational agent to combine with lenalidomide...
  47. pmc Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival
    Nathalie A Johnson
    Department of Pathology and Laboratory Medicine, British Columbia Cancer Agency, Vancouver, Canada
    Blood 113:3773-80. 2009
    ..Exon 5 of the MS4A1 gene coding for the extracellular component of the CD20 antigen was sequenced in 15 samples...
  48. doi Does rituximab have a place in treating classic hodgkin lymphoma?
    Yasuhiro Oki
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 429, Houston, TX 77030, USA
    Curr Hematol Malig Rep 5:135-9. 2010
    ..Of particular interest is the CD20 antigen, because it is expressed not only on a small fraction of HRS cells but also on the benign reactive B cells in ..
  49. doi HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells
    R Shimizu
    Division of Stem Cell Regulation, Center for Molecular Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan
    Leukemia 24:1760-8. 2010
    ..HDAC) inhibitors augment the cytotoxic activity of rituximab by enhancing the surface expression of CD20 antigen on lymphoma cells...
  50. ncbi Monoclonal antibody FMC7 detects a conformational epitope on the CD20 molecule: evidence from phenotyping after rituxan therapy and transfectant cell analyses
    S Serke
    Department of Hematology and Oncology, Humboldt University, Berlin, Germany
    Cytometry 46:98-104. 2001
    ..Our data indicate that FMC7 binds to a particular conformation of the CD20 antigen, probably to a multimeric CD20 complex...
  51. ncbi [Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases]
    Jia Yu Ling
    State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, P R China
    Ai Zheng 26:418-22. 2007
    ..This study was to analyze the immunophenotypic characteristics of lymphocytic leukemia and NHL with bone marrow involvement using flow cytometry (FCM)...
  52. ncbi High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study
    Thomas M Behr
    Department of Nuclear Medicine, Georg August University of Gottingen, Gottingen, Germany
    Cancer 94:1363-72. 2002
    b>CD20 has been used successfully as a target molecule for conventional low-dose, as well as high-dose, myeloablative radioimmunotherapy (RIT) of B-cell non-Hodgkin lymphoma (NHL)...
  53. ncbi Changes in antigen expression on B lymphocytes during HIV infection
    L Ginaldi
    Department of Internal Medicine and Public Health, University of L Aquila, Italy
    Pathobiology 66:17-23. 1998
    ..We investigated the level of expression of a series of constitutive surface markers in B lymphocytes (HLA-DR, CD19, CD20, CD21, CD22) from 30 HIV-seropositive adult patients and 20 normal controls...
  54. doi Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature
    Ofir Wolach
    Internal Medicine A, and Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center Beilinson Hospital, Petah Tikva, Israel
    Medicine (Baltimore) 89:308-18. 2010
    Rituximab is a chimeric monoclonal antibody against CD20 that is used mainly for the treatment of CD20-positive lymphoma...
  55. ncbi Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma
    T E Witzig
    Division of Internal Medicine and Hematology, Mayo Clinic, Rochester 55905, USA
    Cancer Chemother Pharmacol 48:S91-5. 2001
    Clinical trials of an yttrium-90 (90Y)-conjugated monoclonal antibody to CD20 in patients with relapsed B cell non-Hodgkin lymphoma (NHL) are reviewed...
  56. doi Proliferating active cells, lymphocyte subsets, and dendritic cells in recurrent tonsillitis: their effect on hypertrophy
    Necat Alatas
    Baskent Universitesi, Konya Arastirma Uygulama Merkezi KBB AD, Hocacihan Mahalle, Saray Cad, No 1, Selcuklu, TR 42080 Konya, Turkey
    Arch Otolaryngol Head Neck Surg 134:477-83. 2008
    ..To investigate the causes of hypertrophy in recurrent tonsillitis with hypertrophy (RTTH)...
  57. doi Evaluation of the profile of the immune cell infiltrate in lichen planus, discoid lupus erythematosus, and chronic dermatitis
    Mahmoud Rezk A Hussein
    Department of Pathology, Faculty of Medicine, Assuit University Hospitals, Assuit, Egypt
    Pathology 40:682-93. 2008
    ..This investigation tries to test this hypothesis and to characterise immune cells in interface dermatitis...
  58. pmc Phylogenetic analysis of the MS4A and TMEM176 gene families
    Jonathan Zuccolo
    Department of Biochemistry and Molecular Biology, University of Calgary, Calgary, Alberta, Canada
    PLoS ONE 5:e9369. 2010
    The MS4A gene family in humans includes CD20 (MS4A1), FcRbeta (MS4A2), Htm4 (MS4A3), and at least 13 other syntenic genes encoding membrane proteins, most having characteristic tetraspanning topology...
  59. ncbi Novel monoclonal antibodies for the treatment of chronic lymphocytic leukemia
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, 93 510 Lodz, ul Ciołkowskiego 2, Poland
    Curr Cancer Drug Targets 8:156-71. 2008
    ..More recently the introduction of monoclonal antibodies (mAb), especially rituximab directed against CD20 and alemtuzumab directed against CD52, has renewed interest in CLL therapy...
  60. pmc γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody
    Mounia Sabrina Braza
    INSERM U1040, Montpellier, France
    Haematologica 96:400-7. 2011
    Anti-CD20 monoclonal antibodies are major therapeutic agents for patients with follicular lymphoma and work through complement-mediated cytotoxicity and antibody-dependent cellular cytotoxicity...
  61. ncbi [Human/mouse chimeric anti-CD20 monoclonal antibody enhances antigen presentation in dendritic cells and induces anti-lymphoma CTL effects]
    Li Mei Ai
    Department of Hematology, Peking University First Hospital, Beijing 100034, China
    Zhongguo Shi Yan Xue Ye Xue Za Zhi 15:1247-52. 2007
    In order to investigate the cellular immunoresponses mediated by chimeric anti-CD20 monoclonal antibody (anti-CD20 McAb) through dendritic cells (DCs), mononuclear cells were isolated from human peripheral blood (PBMNC) and DCs from ..
  62. ncbi Fas receptor clustering and involvement of the death receptor pathway in rituximab-mediated apoptosis with concomitant sensitization of lymphoma B cells to fas-induced apoptosis
    Alja J Stel
    University Medical Center Groningen, Department of Pathology and Laboratory Medicine, Section Medical Biology Laboratory Tumor Immunology, Groningen, The Netherlands
    J Immunol 178:2287-95. 2007
    Ab binding to CD20 has been shown to induce apoptosis in B cells. In this study, we demonstrate that rituximab sensitizes lymphoma B cells to Fas-induced apoptosis in a caspase-8-dependent manner...
  63. doi In vitro evaluation of radioprotective and radiosensitizing effects of rituximab
    Nirav S Kapadia
    School of Medicine, The Johns Hopkins University, Baltimore, MD 21287 0817, USA
    J Nucl Med 49:674-8. 2008
    Clinical radioimmunotherapies with anti-CD20 monoclonal antibodies involve administering a predose of unlabeled anti-CD20 antibodies to favorably alter the biodistribution profile of the subsequently administered radiolabeled antibodies ..
  64. ncbi Expression of calcium-permeable cation channel CD20 accelerates progression through the G1 phase in Balb/c 3T3 cells
    M Kanzaki
    Department of Cell Biology, Gunma University, Maebashi, Japan
    J Biol Chem 270:13099-104. 1995
    b>CD20 is a transmembrane protein that functions as a Ca(2+)-permeable cation channel (Bubien, J. K., Zhou, L. J., Bell, P. D., Frizzel, R. A., and Tedder, T. F. (1993) J. Cell Biol...
  65. ncbi Antigen modulation followed by quantitative flow cytometry of B-chronic lymphocytic leukemia cells after treatment
    J Kusenda
    Cancer Research Institute, Slovak Academy of Sciences, Bratislava, Slovak Republic
    Neoplasma 51:97-102. 2004
    ..B-CLL cells we used immunological marker analysis of surface markers characteristic for B-CLL pattern: CD5, CD19, CD20, CD23 and HLA DR and enumeration of fluorescence intensity of these markers given by molecular equivalent of ..
  66. pmc Design and synthesis of bis-biotin-containing reagents for applications utilizing monoclonal antibody-based pretargeting systems with streptavidin mutants
    D Scott Wilbur
    Department of Radiation Oncology, University of Washington, Seattle, Washington 98105, USA
    Bioconjug Chem 21:1225-38. 2010
    Previous studies have shown that pretargeting protocols, using cancer-targeting fusion proteins, composed of 4 anti-CD20 single chain Fv (scFv) fragments and streptavidin (scFv(4)-SAv), followed by a biotinylated dendrimeric N-acetyl-..
  67. ncbi Simultaneous effects of lead and cadmium on NK cell activity and some phenotypic parameters
    B Yucesoy
    Department of Toxicology, Faculty of Pharmacy, Ankara University, Tandogan, Turkey
    Immunopharmacol Immunotoxicol 19:339-48. 1997
    ..In the present paper, we investigated the simultaneous effects of lead and cadmium on NK cell activity and CD4+, CD20+ cell percentages in the workers and compared the data with control and lead-exposed groups...
  68. ncbi Mantle cell lymphoma: non-myeloablative versus dose-intensive therapy
    Frederick B Hagemeister
    The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Leuk Lymphoma 44:S69-75. 2003
    ..In recent years, the use of the chimeric monoclonal antibody rituximab, which is directed against the CD20 antigen, has provided new possibilities for the treatment of MCL...
  69. ncbi B cells as a therapeutic target in autoimmune diseases other than rheumatoid arthritis
    R J Looney
    University of Rochester, 601 Elmwood Avenue, Rm G 6454, Rochester, NY 14642, USA
    Rheumatology (Oxford) 44:ii13-ii17. 2005
    Selective B-cell depletion with anti-CD20 therapy is a promising novel treatment option for patients with refractory autoimmune disease...
  70. ncbi Inflammatory and autoimmune complications of common variable immune deficiency
    Adina Kay Knight
    Clinical Immunology, Mount Sinai School of Medicine, Room 1120, Box 1089, 1425 Madison Ave, New York 10029, USA
    Autoimmun Rev 5:156-9. 2006
    ..TNF antagonists and anti-CD20 immunomodulators have shown some efficacy in CVID in a few patients; further controlled studies are needed to ..
  71. doi Plasmacytic hyperplasia in age-related Epstein-Barr virus-associated lymphoproliferative disorders: a report of two cases
    Masaru Kojima
    Department of Pathology and Clinical Laboratories, Gunma Cancer Center Hospital, 617 1, Takabayashinishi cho, Ohta 373 8550, Japan
    Pathol Res Pract 204:267-72. 2008
    ..Hodgkin (H) and Reed-Sternberg (RS) cells were CD3-, CD20+, CD15-. CD30+, CD45RB+, and latent membrane antigen-1+...
  72. doi Castleman's disease--a two compartment model of HHV8 infection
    Klaus Martin Schulte
    Department of Endocrine Surgery, King s College Hospital, Denmark Hill, London SE5 9RS, UK
    Nat Rev Clin Oncol 7:533-43. 2010
    ..Surgery produces excellent results in unicentric disease, while multicentric disease responds to anti-CD20 therapy or IL-6 and chemotherapy...
  73. doi Management of acute and refractory Kawasaki disease
    Carline E Tacke
    Department of Pediatric Hematology, Immunology and Infectious Diseases, Emma Children s Hospital, Academic Medical Center, H7 230, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Expert Rev Anti Infect Ther 10:1203-15. 2012
    ..options include further dose(s) of IVIG, corticosteroids, TNF-α blockade, cyclosporin A, anti-IL-1 and anti-CD20 therapy...
  74. doi A humanized mouse identifies the bone marrow as a niche with low therapeutic IgG activity
    Anja Lux
    Institute of Genetics, Department of Biology, University of Erlangen Nurnberg, Erwin Rommelstrasse 3, 91058 Erlangen, Germany
    Cell Rep 7:236-48. 2014
    ..Using a model of B cell depletion with different human IgG variants that recognize CD20, we show that this humanized mouse model can provide unique insights into the mechanism of human IgG activity in ..
  75. ncbi Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma
    M S Kaminski
    Department of Internal Medicine, University of Michigan, Ann Arbor 48109 0724, USA
    J Clin Oncol 14:1974-81. 1996
    The CD20 B-lymphocyte surface antigen expressed by B-cell lymphomas is an attractive target for radioimmunotherapy, treatment using radiolabeled antibodies...
  76. ncbi Expression of activation markers CD23 and CD69 in B-cell non-Hodgkin's lymphoma
    M Erlanson
    Department of Oncology, Umea University, Sweden
    Eur J Haematol 60:125-32. 1998
    ..Ninety samples from 84 patients with NHL of B cell type were studied for the expression of CD23 and CD69 in CD20+ B cells by flow cytometric dual parameter analysis...
  77. ncbi Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients
    N Milpied
    CHU Hotel Dieu, Nantes, France
    Ann Oncol 11:113-6. 2000
    ..We report the activity of a humanized anti CD 20 Mo Ab (Rituximab-MABTHERA Roche) in 32 episodes of BLPD treated in 14 French centers...
  78. ncbi In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma
    M T Voso
    Department of Internal Medicine V, University of Heidelberg, and German Cancer Research Centre, Heidelberg, Germany
    Br J Haematol 109:729-35. 2000
    ..5 and 11.5 d (range 11-24 and 9-24 d) respectively. In conclusion, the addition of the CD20 antibody to chemotherapy ensured tumour depletion in vivo and allowed the collection of PBSCs devoid of tumour ..
  79. ncbi The polyneuropathy associated with Waldenström's macroglobulinaemia can be treated effectively with chemotherapy and the anti-CD20 monoclonal antibody rituximab
    R Weide
    Haematology Oncology Group Practice, Neversstrasse 5, Koblenz, Germany
    Br J Haematol 109:838-41. 2000
    ..This is the first report showing that WM-associated polyneuropathy can be treated effectively with a combination of chemotherapy and the anti-CD20 monoclonal antibody rituximab.
  80. ncbi Pretreatment with interleukin-2 modulates perioperative immunodysfunction in patients with renal cell carcinoma
    M Bohm
    Department of Urology, Otto von Guericke University, Magdeburg, Germany
    Folia Biol (Praha) 49:63-8. 2003
    ..and humoral immunity (differential blood count, T-cell markers CD2, CD3, CD4, and CD8, B-cell markers CD19 and CD20, monocyte markers CD13 and CD14, NK-cell marker CD16, activation markers CD25, CD26, CD69 and HLA-DR, and cytokines ..
  81. ncbi CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts
    H T Claude Chan
    Tenovus Research Laboratory, Cancer Sciences Division, School of Medicine, General Hospital, Tremona Road, Southampton, SO16 6YD United Kingdom
    Cancer Res 63:5480-9. 2003
    ..In the current study, CD20-induced apoptosis was investigated with a panel of anti-CD20 monoclonal antibodies (mAb) in a wide range of cell ..
  82. ncbi Monoclonal antibody treatment of orbital lymphoma
    Timothy J Sullivan
    Department of Ophthalmology, University of Queensland, Royal Brisbane Hospital, Herston, Queensland, Australia
    Ophthal Plast Reconstr Surg 20:103-6. 2004
    To describe the use of an anti-CD20 monoclonal antibody, Rituximab, in the treatment of orbital lymphoma.
  83. ncbi Treatment of SLE with anti-CD20 monoclonal antibody
    R John Looney
    Allergy Immunology, Rheumatology Unit, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    Curr Dir Autoimmun 8:193-205. 2005
    ..This article will review the role of B cells in human SLE as well as the currently available data on the treatment of SLE by depleting B cells with anti-CD20 (rituximab).
  84. pmc Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis
    E Janas
    Rheumatoid Arthritis Biology, RI CEDD, Stevenage, UK
    Clin Exp Immunol 139:439-46. 2005
    Rituxan, a chimeric anti-CD20 antibody, is the first antibody approved for immunotherapy in non-Hodgkin's B-cell lymphoma and other B-cell lymphoproliferative disorders...
  85. ncbi Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation
    S Gellrich
    Department of Dermatology, Venerology and Allergy, Medical Faculty Charité, Humboldt University Berlin, Schumannstr 20 21, 10117 Berlin, Germany
    Br J Dermatol 153:167-73. 2005
    ..Since 1997 the recombinant, chimeric anti-CD20 antibody rituximab has been used in patients suffering from non-Hodgkin's B-cell lymphomas...
  86. ncbi Clinical implications of blast immunophenotypes in myelodysplastic syndromes
    Kiyoyuki Ogata
    Division of Hematology, Department of Medicine, Nippon Medical School, Tokyo, Japan
    Leuk Lymphoma 46:1269-74. 2005
    ..1) MDS blasts were usually CD34( + )CD38( + )HLA-DR( + )CD13( + )CD33( + )CD2(-)CD3(-)CD5(-)CD8(-)CD19(-)CD20(-) in flow cytometric analysis and often lacked myeloperoxidase in cytochemistry, regardless of the MDS subtype...
  87. pmc Neutrophilic granulocytes are the predominant cell type infiltrating pancreatic islets in contact with ABO-compatible blood
    L Moberg
    Department of Oncology, Radiology and Clinical Immunology, Division of Clinical Immunology, Uppsala University Hospital, Sweden
    Clin Exp Immunol 142:125-31. 2005
    ..eosinophilic granulocytes (NaCN + H(2)O(2)), macrophages (CD68), dendritic cells (CD209/DC-SIGN), B cells (CD20) and T cells (CD4, CD8)...
  88. ncbi Immunohistochemical and ultrastructural investigation on cutaneous neuroendocrine carcinoma: report of a case and review of the literature
    Hideaki Ishii
    Department of Pathology, Tokyo Medical University, 6 1 1 Shinjuku, Tokyo 160 8402, Japan
    Med Mol Morphol 39:164-8. 2006
    ..Immunohistochemistry tests gave negative results for LCA, UCHL-1, CD3, and CD20, thereby excluding malignant lymphoma, and the negative results for S-100 protein and HMB-45 ruled out malignant ..
  89. ncbi Chimeric T-cell receptors: new challenges for targeted immunotherapy in hematologic malignancies
    Ettore Biagi
    Centro di Ricerca Matilde Tettamanti, Department of Pediatrics, University of Milano Bicocca, San Gerardo Hospital, Monza, Milan, Italy
    Haematologica 92:381-8. 2007
    ..Thus, CD19 and CD20 have been targeted for B-cell lymphoid tumors (acute lymphoblastic leukemia-ALL, lymphomas and chronic lymphocytic ..
  90. doi Reactivity with TdT in Merkel cell carcinoma: a potential diagnostic pitfall
    Cary J Buresh
    Immunohistochemistry Division, ProPath Laboratory, Dallas, TX 75247, USA
    Am J Clin Pathol 129:894-8. 2008
    ..with TdT in MCC could represent a diagnostic pitfall in the differential diagnosis with lymphoblastic lymphoma, particularly because the latter may lack CD45 and/or CD20, yet both neoplasms may express PAX-5, a B-cell-associated marker.
  91. doi A requirement for calcium in the caspase-independent killing of Burkitt lymphoma cell lines by Rituximab
    Ian Daniels
    David Evans Medical Research Centre, Nottingham University Hospitals Trust, City Hospital Campus, Nottingham, UK
    Br J Haematol 142:394-403. 2008
    ..Together, these data suggest that ligation of the CD20 receptor with rituximab allows a slow sustained influx of Ca(2+) from the external environment that under certain ..
  92. doi Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders
    H F Petereit
    Department of Neurology, Heilig Geist Krankenhaus, Koln, Germany
    Mult Scler 15:189-92. 2009
    Rituximab, a monoclonal antibody against the B-cell-specific surface protein CD20, is being evaluated for treatment of multiple sclerosis and neuromyelitis optica. Both diseases are restricted to the brain and cerebrospinal fluid (CSF)...
  93. ncbi [Individualizing treatment of refractory and relapsed ITP in adults and its development of study]
    Yu Huang
    Department of Geriatric Hematology, Chinese PLA General Hospital, Beijing 100853, China Tumor Center of the First Hospital of Jilin University, Changchun 130021, Jilin Province, China
    Zhongguo Shi Yan Xue Ye Xue Za Zhi 17:1609-15. 2009
    ..This article summarizes all the treatment for refractory ITP, and highlights new therapies, including the anti-CD20 antibody, thrombopoietic agents, TPO receptor agonist and HSCT...
  94. ncbi Splenectomy--a therapeutic option in splenic marginal zone cell lymphoma
    Ana Maria Vladareanu
    Department of Hematology, Emergency Universitary Hospital Bucharest, Carol Davila University of Medicine and Pharmacy, Bucharest UMFCD, Romania
    Rom J Intern Med 47:191-9. 2009
    ..The laboratory tests confirmed leucocytosis with lymphocytosis--a clonal population of B lymphocytes CD20+ CD19+ CD23+/- CD79b+(low), CD43+ FMC7+ CD5+ CD38+ ZAP70+ cyclin D1-...
  95. ncbi Mucosa-associated lymphoid tissue lymphoma of the appendix vermiformis
    Tatsuya Miyazaki
    Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Saitama, Japan
    Int Surg 95:27-32. 2010
    ..The centrocyte-like cells were immunohistochemically positive for CD20 and CD79a, and were negative for BCL2, CD3, CD5, and CD10; this was compatible with primary mucosa-associated ..
  96. doi Sustained clinical response to rituximab in a case of life-threatening overlap subepidermal autoimmune blistering disease
    Yaohan Li
    University of Oklahoma College of Medicine, USA
    J Am Acad Dermatol 64:773-8. 2011
    ..Rituximab, a chimeric recombinant monoclonal antibody targeting CD20(+) B cells, has recently been suggested to be effective in the treatment of pemphigus with relatively few adverse ..
  97. pmc B-cell depletion reveals a role for antibodies in the control of chronic HIV-1 infection
    Kuan Hsiang G Huang
    Nuffield Department of Medicine and NIHR Biomedical Research Centre, Oxford Martin School, Peter Medawar Building for Pathogen Research, University of Oxford, South Parks Road, Oxford OX1 3SY, UK
    Nat Commun 1:102. 2010
    ..taking antiretroviral drugs and was treated for pre-existing low-grade lymphoplasmacytoid lymphoma by depletion of CD20+ B cells using rituximab...
  98. pmc Remitting-relapsing multiple sclerosis patient refractory to conventional treatments and bone marrow transplantation who responded to natalizumab
    Athanasia Mouzaki
    Division of Hematology, Department of Internal Medicine, Patras, Greece
    Int J Gen Med 3:313-20. 2010
    ..Natalizumab treatment in patient A resulted in lymphocytosis and increased levels of CD20+/CD20+CD5+ B cells and T regulatory cells (Tregs)...
  99. ncbi Novel treatments for systemic lupus erythematosus
    Mary Gayed
    Sandwell and West Birmingham Hospitals NHS Trust, Department of Rheumatology, City Hospital, Birmingham, B18 7QH, UK
    Curr Opin Investig Drugs 11:1256-64. 2010
    ..autoantibody formation in SLE include the use of mAbs that modulate and/or deplete B-cells (anti-CD22 and anti-CD20 antibodies, respectively), or that interfere with the stimulatory effects of the soluble factor B-lymphocyte ..
  100. doi Enterovirus 71 meningoencephalitis complicating rituximab therapy
    Rebekah Ahmed
    Institute of Clinical Neurosciences, Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia
    J Neurol Sci 305:149-51. 2011
    We describe a fatal case of proven enterovirus 71 meningoencephalitis complicating monoclonal anti-CD20 antibody therapy for non-Hodgkin's lymphoma...
  101. pmc Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis
    Simone Lanini
    National Institute for Infectious Diseases, INMI Lazzaro Spallanzani Via Portuense, 292 00149 Rome, Italy
    BMC Med 9:36. 2011
    ..been reported to improve the end of treatment outcome in patients affected by CD-20 positive malignant lymphomas (CD20+ ML)...

Research Grants68

  1. Mechanism of Antibody Therapy in Human B Cell Lymphoma
    Wen Kai Weng; Fiscal Year: 2007
    ..Recently, the successful use of non-toxic monoclonal anti-CD20 antibody, rituximab, to treat B cell lymphoma has produced a great deal of excitement and new hope...
  2. BRENDA MARIE SANDMAIER; Fiscal Year: 2016
    ..CD20 negative NHL, such as T-cell NHL, do not benefit from targeted intensification of therapy directed at the CD20 antigen. Radiolabeled anti-CD45 MAbs have been highly effective as part of a conditioning regimen for HCT for relapsed ..
  3. Sherie L Morrison; Fiscal Year: 2015
    ..We have recently succeeded in producing fusion proteins targeting the CD20 antigen expressed on the surface of B cell non-Hodgkin lymphomas...
  4. Targeted therapy of pancreatic cancer with in vivo radionuclide generator
    Ekaterina Dadachova; Fiscal Year: 2012
    ..to treat refractory and recurrent lymphomas, with two radiolabeled monoclonal antibodies (mAb) targeted against CD20 (Zevalin(R) and Bexxar(R))...
  5. Rituximab Therapy in Refractory Adult and Juvenile IIM
    CHARLES ODDIS; Fiscal Year: 2010
    ..Rituximab is a chimeric, murine-human, genetically engineered monoclonal antibody directed against the CD20 antigen found on the surface B-lymphocytes and is known to deplete B cells when administered intravenously...
  6. Rituximab Therapy in Refractory Adult and Juvenile IIM
    CHARLES ODDIS; Fiscal Year: 2009
    ..Rituximab is a chimeric, murine-human, genetically engineered monoclonal antibody directed against the CD20 antigen found on the surface B-lymphocytes and is known to deplete B cells when administered intravenously...
  7. John M Timmerman; Fiscal Year: 2014
    DESCRIPTION (provided by applicant): Anti-CD20 monoclonal antibodies (mAbs) such as rituximab have become a cornerstone in the therapy of B cell non-Hodgkin lymphomas (NHL), but are only partially effective, as most patients eventually ..
  8. Oliver W Press; Fiscal Year: 2015
    ..with B and T cell lymphomas (Aim 1), compare and contrast targeting of lymphoma cells with radiolabeled anti-CD20 and anti-CD45 RAb (Aim 2), compare the relative merits of 111ln-BC8 and 86Y-BC8 for conducting trace-labeled ..
  9. Edward A Neuwelt; Fiscal Year: 2016
    ..after BBBD in newly diagnosed and recurrent PCNSL, and radioimmunotherapy with yttrium-90 labeled anti- CD20 mAb ibritumomab tiuxetan (Zevalin")...
  10. Oliver W Press; Fiscal Year: 2016
    Preliminary clinical trials have demonstrated that radiolabeled anti-CD20 monoclonal antibodies can achieve remissions in 65-90% of lymphoma patients failing chemotherapy...
  11. Identification of biomarkers of fatty acid intake
    Hannia Campos; Fiscal Year: 2002
    ..T lymphocytes (CTL) which have been genetically modified to express a chimeric T cell receptor recognizing the CD20 antigen present on B cell lymphomas...
  12. Martin G Pomper; Fiscal Year: 2014
    ..g., those expressing the B cell surface molecule CD20. Monoclonal antibodies and radioimmunoconjugates such as [131I]Tositumomab (Bexxar") and [90Y]ibritumomab iuxetan (..
  13. Combined radio- and immunotherapy of aggressive NHL
    William A Wegener; Fiscal Year: 2013
    ..NHL Phase I/II clinical trials with 90Y-epratuzumab (humanized anti-CD22 IgG) and veltuzumab (humanized anti-CD20 IgG) have established the maximum tolerated dose (MTD) of a fractionated injection of 90Y-epratuzumab, and the ..
  14. Nanobiotechnology for the Treatment of Mantle Cell Lymphoma
    Trudy Forte; Fiscal Year: 2009
    ..lipid particles, termed nanodisks (ND), protein engineering methods will be employed to target ATRA-ND to the CD20 antigen present on the surface of B lymphocytes...
  15. Rituximab Elicitation of Tumor Specific T-cell Responses in Lymphoma Patients
    Steven H Bernstein; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Rituximab, a chimeric monoclonal antibody directed against CD20, has shown significant therapeutic activity in patients with follicular lymphoma (FL), yet it's exact mechanism of action has not ..
  16. Eric Meffre; Fiscal Year: 2016
    ..as well as in humans by successful treatment of rheumatoid arthritis (RA) and other autoimmune diseases with anti-CD20 monoclonal antibodies that eliminate B cells...
  17. Using the Allergic Immune System to Target Cancer
    Joseph Mollick; Fiscal Year: 2009
    ..Monoclonal antibodies to CD20 and two glycosylated forms of MUC1 will be humanized...
  18. Optimizing Therapeutic Index of mAb-IFN_alpha Molecule to Treat Lymphoma
    SANJAY DEEP KHARE; Fiscal Year: 2012
    ..This proposal specifically focuses to optimize anti-CD20-IFN[unreadable] fusion molecule to treat human B cell malignancies...
  19. Brian Till; Fiscal Year: 2016
    DESCRIPTION (provided by applicant): Optimization of adoptive immunotherapy with autologous CD20-specific T cells Non-Hodgkin lymphoma is diagnosed in more than 70,000 Americans each year, and aggressive B-cell lymphomas comprise ..
  20. CD20-targeted IL-15 immunotherapeutic for B-cell malignancies
    Hing C Wong; Fiscal Year: 2012
    ..The majority of NHL cases are of B-cell origin and more than 90% express the leukocyte antigen CD20, making these cancers amenable to targeted therapeutic approaches...
  21. Stephen J Forman; Fiscal Year: 2015
    ..In Project 3 investigators will test a molecularly engineered novel anti-CD20 IL-2 immunocytokine for the treatment of patients with 0020"^ lymphoma...
  22. Characterization and Development of a Coiled-Coil to Treat Non-Hodgkin Lymphoma
    Michael Jacobsen; Fiscal Year: 2013
    ..Here, the assembly of coiled- coils was applied to crosslink CD20 receptors on B-cell surfaces, leading to specific induction of apoptosis in these cells...
  23. PHASE I STUDY OF ANTICD20/STREPTAVIDIN
    Hazel Breitz; Fiscal Year: 2001
    DESCRIPTION (applicant's abstract): The objective of this proposal is to test whether a genetically engineered anti-CD20/streptavidin fusion protein can be used for the initial pretargeting step in the treatment of non-Hodgkin' lymphoma ..
  24. David V Serreze; Fiscal Year: 2016
    ..Results from a recent clinical trial indicated transient depletion of B-lymphocytes with the CD20 specific rituximab antibody did not provide for long-term attenuation of diabetogenic autoimmunity...
  25. B cells in CNS autoimmunity
    Scott S Zamvil; Fiscal Year: 2013
    ..Recent clinical results suggest that anti-CD20 B cell depletion may be effective in MS treatment...
  26. miRNA HD Array Platform
    Bruce E Seligmann; Fiscal Year: 2010
    ..biopsies from patients with diffuse large B cell lymphoma (DLBCL), who subsequently received chemotherapy plus anti-CD20 monoclonal Ritixan, will be tested...
  27. TRANSCRIPTIONAL REPRESSION AND ACTIVATION BY YY1
    Yang Shi; Fiscal Year: 2010
    ..Rituximab (chimeric anti-CD20 monoclonal antibody) is the first FDA approved antitumor antibody for the treatment of B-non-Hodgkin's ..
  28. CD20 DNA VACCINATION FOR B-CELL LYMPHOMA
    Maria Lia Palomba; Fiscal Year: 2010
    ..Treatment with anti-CD20 monoclonal antibody, rituximab, is the most successful immune therapy of cancer ever accomplished, and demonstrates ..
  29. Type 1 Diabetes TrialNet at Indiana University Clinical Center
    Linda DiMeglio; Fiscal Year: 2013
    ..One such agent, the anti-CD20 drug rituximab (RituxanR, Genentech, South San Francisco and Biogen) originally developed for treatment of B-cell ..
  30. Molecular Signatures to Improve Diagnosis and Outcome Pr
    Wing Chan; Fiscal Year: 2009
    ..Since existing prognosticators were derived from the study of archival cases prior to the availablility of anti-CD20 therapy, they will be re-evaluated in patients treated with current therapeutic regimens...
  31. Development of an interferon-alpha-veltuzumab conjugate for CD20-targeted therapy
    EDMUND ROSSI; Fiscal Year: 2009
    ..The prototype MAb-IFNa, 20-2b, uses the humanized anti-CD20 MAb, veltuzumab, for targeted delivery of IFNa2b for therapy of B-cell lymphoma...
  32. Hyun Soon Chong; Fiscal Year: 2016
    ..containing Y-90 (beta particle-emitting radionuclide), 1B4M-DTPA (bifunctional ligand), and Rituximab (anti-CD20 antibody) significantly enhanced the overall response rate in the treatment of non- Hodgkin's lymphoma (NHL) ..
  33. Development of an interferon-alpha-veltuzumab conjugate for CD20-targeted therapy
    Edmund A Rossi; Fiscal Year: 2011
    ..Combination therapy of NHL using IFNa2 and the anti-CD20 monoclonal antibody (MAb) rituximab is more effective than either agent as a monotherapy...
  34. SYNERGISTIC CHEMO RADIOIMMUNOTHERAPY FOR B LYMPHOMAS
    Timothy Johnson; Fiscal Year: 2003
    ..Preliminary data demonstrate marked synergism in vitro between Iodine-131-radiolabeled anti-CD20 antibody and nucleoside analogs; moderate synergism with topoisomerase inhibitors; and non synergism with cisplatin ..
  35. RADIOIMMUNOTHERAPY OF LYMPHOMA
    Mark Kaminski; Fiscal Year: 2000
    ..We have now demonstrated that radioimmunotherapy (RIT) with 131-I-labeled anti-B1 (anti-CD20) results in major and durable tumor responses in virtually all patients (13 of 13, 10 complete remissions) with ..
  36. RADIOIMMUNOTHERAPY STRATEGIES IN NONHODGKINS LYMPHOMAS
    MELISSA CORCORAN; Fiscal Year: 1999
    ..organ ratios of absorbed radiation in a mouse xenograft model utilizing streptavidin-biotin "pretargeted" anti-CD20 antibody and the applicants' current "one step" 131I-anti-CD20 antibody...
  37. ANTI-CD20 ANTIBODY THERAPY OF NHL-- MECHANISM OF ACTION
    David Maloney; Fiscal Year: 2002
    ..mediated effects by evaluating effect on (a) cell proliferation and apoptosis; (b) re-distribution of the CD20 antigen into a insoluble membrane fraction; (c) tyrosine phosphorylation through Src family kinases; (d) calcium ..
  38. MERVYN N WEITZMANN; Fiscal Year: 2016
    ..In Specific Aim 1 we will investigate the impact of B cell depletion in mice in vivo using an anti-CD20 antibody that mimics the agent Rituximab, now used in humans to treat refractory Rheumatoid Arthritis and certain B ..
  39. Yale Autoimmunity Center of Excellence
    Kevan C Herold; Fiscal Year: 2013
    ..The second project is an analysis of autoreactive B cells in T1DM and in patients with T1DM treated with anti-CD20 mAb, in patients with pSS, and in patients with IBD...
  40. AUTOIMMUNITY CENTER OF EXCELLENCE
    David Wofsy; Fiscal Year: 2013
    ..Two concept proposals are presented. Protocol 1 is a phase Ib/lla trial of anti-CD20 plus cyclophosphamide (IVC) as induction therapy in patients with active lupus nephritis...
  41. FUNCTIONAL STUDIES OF HTM4, A CD20/FCE RIB HOMOLOGUE
    CHAKAR ADRA; Fiscal Year: 2002
    ..hematopoietic cell-specific gene encoding a 4-transmembrane protein homologous to the B cell-specific antigen CD20, and the beta-subunit of the high affinity IgE Fc receptor, FcecRIB...
  42. Cornelia Bergmann; Fiscal Year: 2016
    ..immune activation due to ectopic B cell follicle formation, as well as improvement in MS patients treated with anti-CD20 monoclonal Ab rituximab to reduce circulating B cells...
  43. Wei Ding; Fiscal Year: 2015
    ..Bendamustine (an alkylating agent) and Rituximab (an antibody targeting CD20) combination therapies have emerged as one of the effective approaches used in the relapsed CLL;however, only ~15% ..
  44. GENE THERAPEUTIC APPROACH FOR TOLERANCE INDUCTION
    DAVID WILLIAM SCOTT; Fiscal Year: 2013
    ..We will test the hypothesis that anti-CD20 treatments leads to partial depletion of B cells, sparing the tolerogenic MZ cells...
  45. CELLULAR MECHANISMS OF PTLD IN TRANSPLANT RECIPIENTS
    Olivia M Martinez; Fiscal Year: 2012
    ..have been utilized to treat patients with PTLD such as anti-viral drugs, B cell specific antibodies including anti-CD20 (Rituximab) and adoptive cellular immunotherapy. However, each of these approaches has distinct limitations...
  46. Optimized Adaptation of Simian-tropic R5 HIV Clade C to Pig-tailed Macaques
    RUTH MARGRIT RUPRECHT; Fiscal Year: 2013
    ..Select stHIV-C progeny with improved replication fitness in PMs under prolonged depletion of CD8+ and CD20+ cells~ 2...
  47. Jennifer Gordon; Fiscal Year: 2014
    ..It is believed that immunosuppression with potent new classes of immunosuppressive agents, including the anti-CD20 molecule, rituximab, allows JC virus to replicate in patients which leads to the development of PML...
  48. Novel multivalent/multifunctional agents derived from a humanized anti-insulin-li
    Thomas M Cardillo; Fiscal Year: 2010
    ..Past experience with a hexavalent anti-CD20 agent (Hex-hA20) and an anti-CD20-IFN-a2b agent (20-2b) demonstrated superiority in comparison to either the ..
  49. TREATMENT OF ANTI-HLA ANTIBODIES TO PREVENT BOS AFTER LUNG TRANSPLANTATION
    Roger D Yusen; Fiscal Year: 2011
    ..will use a double blind randomized placebo controlled trial to evaluate the efficacy and safety of IVIG and anti-CD20 antibody...
  50. Novel Cellular Therapies for Ph+ leukemia
    RICHARD A contact VAN ETTEN; Fiscal Year: 2010
    ..NK cells engineered to express activating receptors that recognize ligands on B-lymphoid leukemia cells (CD19 and CD20), and test their efficacy in an in vivo immunotherapy model against human Ph+ B-ALL in NOD/SCID/c mice...
  51. Human B1 Cell Immunoglobulin
    Thomas L Rothstein; Fiscal Year: 2013
    ..This gap has now been filled with our recent finding that human B1 cells co-express CD20, CD27 and CD43, and lack expression of CD70...
  52. Alessia Fornoni; Fiscal Year: 2015
    ..FSGS) after transplantation is a highly prevalent condition where rituximab (a monoclonal antibody against CD20) may have a potential indication...
  53. Rituximab for Treatment of Type 1 Diabetes: Impact on JC Viral Proliferation
    MARK DAVID PESCOVITZ; Fiscal Year: 2010
    ..The recently reported, TrialNet-sponsored study using the monoclonal antibody rituximab (anti-CD20) demonstrated that B cells also play a role in the pathogenesis...
  54. JAMES BRUCE BUSSEL; Fiscal Year: 2014
    ..Anti-CD20 (Rituximab, ritux) leads to initial benefit in 50% of ITP patients but3 years after treatment, it appears that only ..
  55. Edward M Schwarz; Fiscal Year: 2016
    DESCRIPTION (provided by applicant): The therapeutic efficacy of TNF antagonists and anti-CD20 B cell depletion therapy in rheumatoid arthritis (RA) have altered pathophysiologic paradigms and generated new questions about underlying ..
  56. Predictive Mathematical Models for Rational Design of Chemoimmunotherapy of Leuke
    Craig A Mullen; Fiscal Year: 2010
    ..kinase inhibitor of the bcr-abl fusion protein);(b) pulsatile methotrexate (an antimetabolite);and (c) anti-CD20 monoclonal antibody...
  57. DANIEL J KASS; Fiscal Year: 2016
    ..double-blind, placebo-controlled Phase II clinical trial to explore the efficacy and safety of rituximab (anti-CD20 monoclonal antibody) vs. placebo, among patients with IPF...
  58. NOVEL SEROTHERAPY STRATEGIES--PLASMA CELL MALIGNANCIES
    STEVEN TREON; Fiscal Year: 2004
    ..These efforts have focused on Muc-1 core protein, a tumor selective antigen found on most MM plasma cells, and CD20, a B- cell specific antigen found on the plasma cells of most WM patients (75-100 percent), and certain MM patients ..
  59. Novel Therapies to Improve Renal and Cardiac Allograft Outcomes
    Anil Chandraker; Fiscal Year: 2013
    ..to conventional immunosuppression (tacrolimus, MMF and rapid steroid taper) versus induction therapy with anti-CD20 mAb (Rituxan) plus conventional immunosuppression...
  60. KENNETH LYNN WRIGHT; Fiscal Year: 2016
    ..NK cells also kill through antibody- dependent cell-mediated cytotoxicity (ADCC). Rutuximab (anti-CD20) therapy induces NK cell mediated ADCC against some lymphomas including Mantle Cell Lymphoma (MCL)...
  61. Center of Cancer Nanotechnology Excellence Focused on Therapy Response
    Sanjiv S Gambhir; Fiscal Year: 2010
    ..biochemical pathways targeted will be the Her-kinase axis with prostate cancer as the initial focus, and CD20/c-myc with lymphoma as the second initial major focus...
  62. Mechanisms of tolerance in recipients of combined kidney and bone marrow transpla
    Megan Sykes; Fiscal Year: 2010
    ..acute humoral rejection episodes occurred in several patients, resulting in the addition of B cell-depleting anti-CD20 mAb to the regimen...
  63. Natarajan Muthusamy; Fiscal Year: 2016
    ..The introduction of the CD20 antibody rituximab combined with chemotherapy (chemoimmunotherapy) was the first intervention that has been shown ..
  64. Ali Naji; Fiscal Year: 2016
    ..of islet transplantation in Cynomolgus macaques utilizing an induction immunotherapy regimen, which included a CD20 specific B cell depleting agent...
  65. FAIM in Immunity and Autoimmunity
    THOMAS ROTHSTEIN; Fiscal Year: 2009
    ..The recent successful use of anti-CD20 to treat patients with autoimmune dyscrasias has re-focused attention on the role of B cells as therapeutic targets...
  66. OPTIMIZING RADIOIMMUNOTHERAPY FOR NON HODGKIN'S LYMPHOMA
    Ajay Gopal; Fiscal Year: 2005
    ..Finally, we hypothesize that augmenting CD20 antigen expression on malignant B cells with cytokines such as GM-CSF and enhancing anti-CD20 Ab mediated apoptosis ..
  67. Anti-CD20 CTL for Therapy of Mantle Cell Lymphoma
    Oliver Press; Fiscal Year: 2007
    ..T lymphocytes that have been genetically modified to express a chimeric T cell receptor recognizing the CD20 antigen present on B cell lymphomas...
  68. Cytokine Dysregulation in GM-CSF Autoimmunity
    Mary Jane Thomassen; Fiscal Year: 2007
    ..Rituximab, a chimeric murine-human monoclonal antibody directed against the B cell-specific membrane antigen CD20, selectively depletes B cells...